Sunovion is a leading pharmaceutical company dedicated to discovering, developing, and bringing to market therapeutic products that advance the science of medicine to improve the lives of patients, their families, and communities. We specialize in treatments that help people challenged by disorders of the central nervous system and respiratory ailments.
At Shire, we enable people with life-altering conditions to lead better lives. We focus on developing and delivering innovative medicines for patients with rare diseases and other specialty conditions. This might be a therapy to treat an extremely rare and life-threatening disease such as Hunter syndrome or Fabry disease, or a medicine for a specialist condition such as ADHD or ulcerative colitis.
To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
Shionogi Inc. is the US subsidiary of Shionogi & Co. Ltd., a pharmaceutical company with headquarters in Osaka, Japan. For over 135 years, Shionogi has been dedicated to developing medicines that protect the health and well-being of patients worldwide. Addressing unmet medical needs and improving quality of life for patients and their families are what drives our company, our philosophy and our teams.
Lilly unites caring with discovery to make life better for people around the world.
Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
The Janssen Pharmaceutical Companies of Johnson & Johnson address some of the most devastating and complex diseases of our age through research and development of prescription medicines including biologics and other novel treatments. Spending more than $6 billion in R&D in 2014, Janssen is investing in a transformative future, changing the way diseases are interpreted, managed and prevented. Our pharmaceutical and biologic medicines are focused in five areas of healthcare. Click on the therapeutic area below to find medicines.
Janssen Pharmaceutical Companies of Johnson & Johnson
Fortress Biotech is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as Fortress Companies.
Allergan is one of the world’s fastest-growing pharmaceutical companies with a deeply established commercial presence in approximately 100 countries.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, ophthalmology, medical aesthetics, gastroenterology, women’s health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world’s third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines.
We believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients’ lives. We are courageous in both decision and action. And we believe that good business means a better world.
That is why we come to work each day. We commit ourselves to scientific rigour, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow.
We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.
To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
We are a science-led global healthcare company with a mission: we want to help people to do more, feel better, live longer.
The vaccines, medicines and consumer healthcare products that we research and develop can improve people’s health and well-being, ultimately helping them to live life to its fullest and contribute to the prosperity of their communities.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Our aspiration is to achieve scientific leadership. To do so we are focusing, prioritising and transforming our efforts to improve the quality of our science and our productivity.
The pursuit of scientific excellence guides everything we do. To achieve scientific leadership we are changing the way we work, making the most of the capabilities we already have and building those we need.
Based on the corporate philosophy of “Takeda-ism” (Integrity: Fairness, Honesty and Perseverance) developed over its long corporate history of more than 230 years, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”
Takeda Pharmaceutical Company Limited
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 17,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
Sanofi is a global healthcare leader focused on patient’s needs, engaged in research, development, manufacturing and marketing of health products, with a diversified offer of medicines, vaccines and innovative therapeutic solutions.
Through the Sanofi Foundation for North America, we strive to reduce healthcare inequalities in the U.S. by making strategic charitable donations and by establishing partnerships with Non-Government Organizations that have broad expertise in our long-term priorities.
At Sanofi, patients and their needs are at the heart of what we do.
Corcept is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.
Orexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology.
Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones.
Our vision is a world where people are healthier and live better.
Our purpose is to make a difference by giving people innovative solutions for healthier lives and happier homes. This means we are expanding our capabilities and investing in innovation to stay ahead of the game.
Established in 1964, Otsuka Pharmaceutical is a total healthcare company. In keeping with its corporate philosophy of “Otsuka-people creating new products for better health worldwide,” it aims to treat illness and sustain day-to-day well-being. With a pharmaceutical business that provides breakthrough treatments for patients around the world, and a nutraceutical business that helps healthy people get even healthier, Otsuka Pharmaceutical researches, develops, produces and sells highly innovative and creative products.
Our mission is to care and cure.
We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.
We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest their money, their time and their ideas in our company.
Neurocrine Biosciences, Inc. of San Diego discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.
The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.
Euthymics Bioscience is developing a novel medicine for alcohol use disorder (AUD) and smoking cessation. The name Euthymics is related to the word “euthymia” which means “mood in the ‘normal’ range, without manic or depressive symptoms.” Euthymics Bioscience is focused on developing therapeutics that help patients with withdrawal symptoms, impulsivity and cravings, all of which are common when being treated for addiction.